Come and join us at the Pharmacy Services 2017 Annual Meeting on Tuesday, October 3, 2017. David Brodersen and Adam Parton will be on hand to answer all of your regulatory compliance questions on USP chapters <797>/<800>, cleanroom qualifications, and environmental monitoring. USP <797>/<800> – REGULATORY EXPECTATIONS What are the challenges we all face […]
About Adam Parton
This author has yet to write their bio.Meanwhile lets just say that we are proud Adam Parton contributed a whooping 6 entries.
Entries by Adam Parton
June 19, 2017 LexaMed is pleased to announce the addition of Jeff Martin to our consulting team. Jeff currently stands as the co-chair for the AAMI Industrial EO Standards working group. With over twenty years of experience, Jeff has national and international industry recognition for his subject matter expertise in terminal sterilization, Quality Systems and operations.
LexaMed is pleased by the overwhelming success through the first quarter of the Growth-Chek™ promotion and is continuing it through June 30,2017. New Customers will continue to receive 50% off their first Growth-Chek™ Order . Excludes special order/custom made suspensions. When ordering, please mention internet ad for new clients. Discount does not apply to shipping/handling […]
FOR IMMEDIATE RELEASE Xiao-qun Zeng Certified NRCM Registrant WASHINGTON, DC—July 26, 2016—Xiao-qun Zeng, Project Team Lead, LexaMed, Ltd, Toledo, OH, is now a Registrant of the National Registry of Certified Microbiologists (NRCM). On June 27, 2016, she became certified as a Specialist Microbiologist in Pharmaceutical and Medical Device Microbiology. Ms. Zeng received her M.S. degree […]
August 18, 2016/in Events /by computol Come and join us at the BioOhio Meeting on Wednesday, September 28, 2016. LexaMed President, Bob Reich will be speaking Join us to learn more about FDA requirements for reprocessing reusable medical devices (cleaning/disinfection/sterilization), AET, Environmental Isolates and Quality Management. For more information, click here Where: Ascend Innovations […]
FDA continues to issue 483s to compounding pharmacies for a lack evidence and cGMP framework in preventing/mitigating beta-lactam cross-contamination Warning Letters and significant FDA 483 observations continue to plague the compounding pharmacy industry with over 40% of compounders inspected receiving Warning Letters and nearly 100% receiving critical observations. One of the more common observations cited […]